NO20091330L - Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav - Google Patents

Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav

Info

Publication number
NO20091330L
NO20091330L NO20091330A NO20091330A NO20091330L NO 20091330 L NO20091330 L NO 20091330L NO 20091330 A NO20091330 A NO 20091330A NO 20091330 A NO20091330 A NO 20091330A NO 20091330 L NO20091330 L NO 20091330L
Authority
NO
Norway
Prior art keywords
derived peptides
methods
peptides
pharmacological
cupredoxin
Prior art date
Application number
NO20091330A
Other languages
English (en)
Norwegian (no)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20091330L publication Critical patent/NO20091330L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20091330A 2006-09-11 2009-03-31 Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav NO20091330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84338806P 2006-09-11 2006-09-11
PCT/US2007/078136 WO2008033820A2 (en) 2006-09-11 2007-09-11 Modifications of cupredoxin derived peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20091330L true NO20091330L (no) 2009-06-05

Family

ID=39184502

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091330A NO20091330L (no) 2006-09-11 2009-03-31 Modifiseringer av kupredoxin avledede peptider samt fremgangsmater for bruk derav

Country Status (14)

Country Link
US (2) US10005821B2 (pt)
EP (1) EP2061487A4 (pt)
JP (2) JP2010502765A (pt)
KR (1) KR20090059148A (pt)
CN (1) CN101600447A (pt)
AU (1) AU2007296614A1 (pt)
BR (1) BRPI0715027A2 (pt)
CA (1) CA2663188A1 (pt)
IL (1) IL197501A0 (pt)
MX (1) MX2009002612A (pt)
NO (1) NO20091330L (pt)
RU (1) RU2009113562A (pt)
SG (1) SG174108A1 (pt)
WO (1) WO2008033820A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
US8158574B2 (en) 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US9968685B2 (en) * 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US8232244B2 (en) 2007-02-08 2012-07-31 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF
WO2008045238A2 (en) * 2006-10-05 2008-04-17 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
AU2007329375A1 (en) 2006-12-04 2008-06-12 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA
JP2011522796A (ja) 2008-05-06 2011-08-04 ニューヨーク ブラッド センター， インコーポレイテッド 抗ウイルス細胞透過性ペプチド
CN103937705B (zh) * 2014-03-10 2016-03-16 赵晗 一株罕见无色杆菌及其在去除重金属离子中的应用
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
GB201700555D0 (en) 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
GB201700557D0 (en) * 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827934A (en) 1988-03-08 1998-10-27 The University Of Wyoming Cytotoxic diphtheria toxin fragments
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
MXPA01011008A (es) 1999-04-30 2003-06-30 Slil Biomedical Corp Conjugados analogos de poliamina y conjugados de quinona novedosos como terapia para canceres y enfermedades de la prostata.
US6800437B1 (en) 1999-08-06 2004-10-05 Tibotec Bvba Method of monitoring a biological system by labeling with an apo metal binding protein
WO2002076380A2 (en) 2001-02-15 2002-10-03 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7556810B2 (en) * 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7491394B2 (en) 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
US7338766B2 (en) 2001-02-15 2008-03-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating malaria with cupredoxin and cytochrome
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
AU2003254065A1 (en) 2002-12-30 2004-07-29 Gryphon Therapeutics, Inc. Backbone anchored thioester and selenoester generators
AU2003220380A1 (en) 2003-03-19 2004-11-19 Bristol-Myers Squibb Company CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH Alpha-HELIX STABILIZERS
GB0321937D0 (en) 2003-09-19 2003-10-22 Univ Liverpool Nanoparticle conjugates and method of production thereof
UA97466C2 (ru) * 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
WO2006062398A2 (en) 2004-12-07 2006-06-15 Applied Nanosystems B.V. Methods for the production and secretion of modified peptides
EP1904642A4 (en) * 2005-07-19 2008-11-26 Univ Illinois TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
WO2008033820A3 (en) 2008-12-18
SG174108A1 (en) 2011-09-29
US20100267608A1 (en) 2010-10-21
AU2007296614A1 (en) 2008-03-20
US10590177B2 (en) 2020-03-17
BRPI0715027A2 (pt) 2013-05-28
JP2014193886A (ja) 2014-10-09
JP2010502765A (ja) 2010-01-28
IL197501A0 (en) 2011-08-01
MX2009002612A (es) 2009-12-15
CN101600447A (zh) 2009-12-09
RU2009113562A (ru) 2010-10-20
WO2008033820A8 (en) 2009-07-30
US10005821B2 (en) 2018-06-26
CA2663188A1 (en) 2008-03-20
EP2061487A2 (en) 2009-05-27
WO2008033820A2 (en) 2008-03-20
EP2061487A4 (en) 2009-12-02
KR20090059148A (ko) 2009-06-10
US20180319848A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
MX2009002612A (es) Modoficaciones de péptidos derivados de cupredoxinas y métodos de uso de los mismos.
MX2019001198A (es) Activadores de moleculas pequeñas de funcion de la enzima parkin.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
DK2137301T3 (da) Adenovirus med mutationer i det endoplasmatiske reticulums retentionsdomæne for E3-19K-proteinet samt deres anvendelse ved cancerbehandling
EP3736294A3 (en) Cd73 blockade
IL308807B2 (en) Combination therapy for treating cancer
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
MY150650A (en) Pyrrolopyrimidine compounds and their uses
WO2012037155A3 (en) Tyrosine kinase inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
EA201291107A1 (ru) Соединения, ингибирующие металлоферменты
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
WO2012129112A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
MX2009005300A (es) Combinacion de un inhibidor de acido desoxirribonucleico polimerasa-alfa y un inhibidor de una cinasa de punto de verificacion para trastornos proliferativos.
WO2010011343A3 (en) Methods for treating viral disorders
NZ599880A (en) Use of bethanechol for treatment of xerostomia
PH12014501937A1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
EP4707400A3 (en) Gene therapies for lysosomal disorders
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
AU2012240222A8 (en) Methods of treating central nervous system tumors
GB2495885A (en) Combination pharmaceutical composition and methods of treating genitourinary system disorders
EP3848036A3 (en) Methods for increasing blood plasma 2'-deoxyuridine (durd) and thymidylate synthase inhibition
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application